India's Piramal sees $1.5 bln rev from florbetaben
MUMBAI, April 16
MUMBAI, April 16 (Reuters) - Indian drugmaker Piramal Healthcare sees revenue potential of $1.5 billion from its newly acquired florbetaben molecule, which could be used to treat Alzheimer's disease, its chairman, Ajay Piramal, said on Monday.
The company will file for U.S. approval of the treatment in late 2012, Piramal added.
Piramal agreed to buy a research and development portfolio from Germany's Bayer AG in a deal that gives the Indian drugmaker commercial and development rights to florbetaben. (Reporting by Kaustubh Kulkarni; Editing by Aradhana Aravindan)
- California passes 'yes-means-yes' campus sexual assault bill
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |
- In town halls, U.S. lawmakers hear voter anger over illegal migrants |
- IBM launches Watson system for research, hopes for breakthroughs
- U.N. says 43 Golan peacekeepers seized by Syria militants, 81 trapped